Effect of ranibizumab combined with vitrectomy on the serum VEGF-A and SDF-1 expression in patients with proliferative diabetic retinopathy

AIM:To discuss the effect of ranibizumab combined with vitrectomy(VT)on the serum vascular endothelial growth factor A(VEGF-A)and human stromal cell derived factor 1(SDF-1)expression in patients with PDR.METHODS: Totally 120 patients with PDR were selected from January 2017 to January 2018 in our hospital, according to the random digital table, they were divided into group A and group B, 60 cases in each group, group A was given VT treatment, group B was given ranibizumab vitreous injection treatment on this basis, the VT operation, complication and VEGF-A, SDF-1, BCVA, CMT were compared between the two groups.RESULTS: The postoperative serum VEGF-A and SDF-1 levels in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than group A(PPPCONCLUSION: ranibizumab combined with VT can effectively improve the serum VEGF-A and SDF-1 levels in patients with PDR, it can reduce the trauma and complications of VT, and improve the BCVA and CMT in patient